miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 19, 2026

Even auto giants know it: the electric car boom is out of charge

View original at uk.finance.yahoo.com
Even auto giants know it: the electric car boom is out of charge Why the West's electric car dream is running out of road Lead “I think the customer has spoken…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Universal Electric Vehicle platform is the most important product he has ever worked on

    80% confidence
  • Regulatory trajectories are steep and ahead of underlying demand

    80% confidence
  • Government sending mixed messages to industry and consumers

    80% confidence
  • The EV plans carmakers set out were too ambitious

    80% confidence
  • Most of the Western carmakers are now facing big issues

    80% confidence
  • Weakening ZEV mandate would undermine investor confidence

    80% confidence
  • Cracking EVs could deliver a modern Model T moment

    80% confidence
  • Global sales volumes haven't returned to pre-pandemic levels

    80% confidence
  • Competition in auto market in 2026 will be even more brutal and bloody

    80% confidence
  • EVs need cost parity with ICE cars and must offer more than just being clean

    80% confidence
  • Chinese have gotten EV pricing right by achieving parity or cheaper than ICE

    80% confidence
  • Not convinced China's ban on below-cost sales will stop price war

    80% confidence
  • Big thing that drives car companies is what their competitors are doing

    80% confidence
  • Green energy transition is a scam

    80% confidence
  • The customer has spoken regarding electric vehicles

    80% confidence
  • Ground-up overhaul is needed to bring down cost of Western-made EVs

    80% confidence
  • F-150 Lightning was the truck of the future

    80% confidence
  • This is us going back to our roots

    80% confidence
  • Prices for consumers will fall and price parity will be met

    80% confidence
  • Many drivers are still not comfortable making the shift to electric vehicles

    80% confidence
  • Fundamental issue is cars are too expensive and compensated by subsidies which doesn't work

    80% confidence
  • Government needs a reality check on EV mandates or risk carmakers pulling out of UK

    80% confidence
  • European consumer adoption of Chinese cars is much faster than Japanese or Korean cars

    80% confidence
  • Western brands will bring cheaper models using LFP battery technology

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com